From GlobeNewswire: 2024-06-14 22:00:00

The Global Dermal Toxicity Testing Market is projected to increase from USD 2.27 billion in 2023 to USD 4.95 billion by 2033, growing at a CAGR during the forecast period. Dermal toxicity testing evaluates the harmful effects of substances on the skin, ensuring consumer safety and regulatory compliance.

The service segment dominates the market with the largest revenue share in 2023, while in-vitro testing holds the largest market share. The skin sensitization test segment leads the global dermal toxicity testing market, with the healthcare industry as the largest end-user segment.

North America leads the market with the largest share, with significant investments in dermal toxicity testing methods. The Asia-Pacific region is expected to grow the fastest, driven by stricter safety standards and a thriving cosmetics sector. Major vendors in the market include SGS S.A., Eurofins Scientific Inc, and Qiagen N.V.

In January 2023, Eurofins Scientific expanded its presence in India with a new state-of-the-art campus in Hyderabad, offering comprehensive services to pharmaceutical and biotech companies. The lab will provide safety toxicology testing, benefiting the company’s geographical footprint. The global dermal toxicity testing market is segmented based on type, testing method, test type, and end-use industry.

Overall, the market for dermal toxicity testing is expected to experience significant growth, driven by increasing regulatory guidelines, advancements in technology, and a focus on consumer safety in various industries worldwide.



Read more at GlobeNewswire: Global Dermal Toxicity Testing Market Size To Exceed USD